Patents by Inventor Robert M. Burk

Robert M. Burk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230399317
    Abstract: Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.
    Type: Application
    Filed: October 20, 2021
    Publication date: December 14, 2023
    Inventors: Charles BOSWORTH, Mark Richard STEWART, Hila BARASH, Nicholas Andrew CHAPMAN, Robert M. BURK, Ian HOLMES, Marc GLEESON, Yair ALSTER, Omer RAFAELI, Jonathan DUNN
  • Publication number: 20230357207
    Abstract: Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.
    Type: Application
    Filed: March 8, 2023
    Publication date: November 9, 2023
    Inventors: Ian HOLMES, Yair ALSTER, Hila BARASH, Charles BOSWORTH, Omer RAFAELI, Marc GLEESON, Mark Richard STEWART, Robert M. BURK, Jonathan DUNN, Nicholas CHAPMAN
  • Patent number: 11634411
    Abstract: Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: April 25, 2023
    Assignee: AZURA OPHTHALMICS LTD.
    Inventors: Ian Holmes, Yair Alster, Hila Barash, Charles Bosworth, Omer Rafaeli, Marc Gleeson, Mark Richard Stewart, Robert M. Burk, Jonathan Dunn, Nicholas Chapman
  • Publication number: 20220354865
    Abstract: Prostamide-containing biodegradable intraocular implants, prostamide compounds, prostamide-containing pharmaceutical compositions, and methods for making and using such implants and compositions for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described.
    Type: Application
    Filed: December 6, 2021
    Publication date: November 10, 2022
    Inventors: Patrick M. Hughes, Jie Shen, Michael R. Robinson, David F. Woodward, Robert M. Burk, Hui Liu, Jinping Wan, Chandrasekar Durairaj, Gyorgy F. Ambrus, Ke Wu, Danny T. Dinh
  • Publication number: 20220332749
    Abstract: Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.
    Type: Application
    Filed: June 15, 2022
    Publication date: October 20, 2022
    Inventors: Ian HOLMES, Yair ALSTER, Hila EPSTEIN-BARASH, Charles BOSWORTH, Omer RAFAELI, Robert M. BURK, Marc GLEESON, Mark Richard STEWART, Jonathan DUNN, Alexander James NICHOLLS
  • Publication number: 20220332748
    Abstract: Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.
    Type: Application
    Filed: April 5, 2021
    Publication date: October 20, 2022
    Inventors: Ian HOLMES, Yair ALSTER, Hila BARASH, Charles BOSWORTH, Omer RAFAELI, Robert M. BURK, Marc GLEESON, Mark Richard STEWART, Jonathan DUNN, Alexander James NICHOLLS
  • Patent number: 11459351
    Abstract: Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.
    Type: Grant
    Filed: April 5, 2021
    Date of Patent: October 4, 2022
    Assignee: AZURA OPHTHALMICS LTD.
    Inventors: Ian Holmes, Yair Alster, Hila Barash, Charles Bosworth, Omer Rafaeli, Robert M. Burk, Marc Gleeson, Mark Richard Stewart, Jonathan Dunn, Alexander James Nicholls
  • Publication number: 20210107899
    Abstract: Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.
    Type: Application
    Filed: December 4, 2020
    Publication date: April 15, 2021
    Inventors: Ian HOLMES, Yair ALSTER, Hila BARASH, Charles BOSWORTH, Omer RAFAELI, Marc GLEESON, Mark Richard STEWART, Robert M. BURK, Jonathan DUNN, Nicholas CHAPMAN
  • Publication number: 20210085689
    Abstract: Prostamide-containing biodegradable intraocular implants, prostamide compounds, prostamide-containing pharmaceutical compositions, and methods for making and using such implants and compositions for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described.
    Type: Application
    Filed: May 6, 2020
    Publication date: March 25, 2021
    Inventors: Patrick M. Hughes, Jie Shen, Michael R. Robinson, David F. Woodward, Robert M. Burk, Hui Liu, Jinping Wan, Chandrasekar Durairaj, Gyorgy F. Ambrus, Ke Wu, Danny T. Dinh
  • Patent number: 10875845
    Abstract: Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: December 29, 2020
    Assignee: AZURA OPHTHALMICS LTD.
    Inventors: Ian Holmes, Yair Alster, Hila Barash, Charles Bosworth, Omer Rafaeli, Marc Gleeson, Mark Richard Stewart, Robert M. Burk, Jonathan Dunn, Nicholas Chapman
  • Publication number: 20200331896
    Abstract: Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.
    Type: Application
    Filed: June 17, 2020
    Publication date: October 22, 2020
    Inventors: Ian HOLMES, Yair ALSTER, Hila BARASH, Charles BOSWORTH, Omer RAFAELI, Marc GLEESON, Mark Richard STEWART, Robert M. BURK, Jonathan DUNN, Nicholas CHAPMAN
  • Patent number: 10668081
    Abstract: Prostamide-containing biodegradable intraocular implants, prostamide compounds, prostamide-containing pharmaceutical compositions, and methods for making and using such implants and compositions for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: June 2, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Patrick M. Hughes, Jie Shen, Michael R. Robinson, David F. Woodward, Robert M. Burk, Hui Liu, Jinping Wan, Chandrasekar Durairaj, Gyorgy F. Ambrus, Ke Wu, Danny T. Dinh
  • Patent number: 10329284
    Abstract: Described herein are ester prodrugs of gamma-lactam compounds of Formula (I): or pharmaceutically acceptable salt thereof, and methods of use of such compounds for the treatment of ocular diseases including, among other things, glaucoma and macular degeneration.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: June 25, 2019
    Assignee: ALLERGAN, INC.
    Inventors: Robert M. Burk, Wha Bin Im
  • Patent number: 10117877
    Abstract: Disclosed herein are methods, compounds, and compositions for fat reduction, and in particular fat reduction without significant hair growth and/or additional hair growth.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: November 6, 2018
    Assignee: ALLERGAN, INC.
    Inventors: Neil J. Poloso, Jenny Wang, David F. Woodward, Robert M. Burk
  • Publication number: 20180161342
    Abstract: Prostamide-containing biodegradable intraocular implants, prostamide compounds, prostamide-containing pharmaceutical compositions, and methods for making and using such implants and compositions for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described.
    Type: Application
    Filed: February 12, 2018
    Publication date: June 14, 2018
    Inventors: Patrick M. Hughes, Jie Shen, Michael R. Robinson, David F. Woodward, Robert M. Burk, Hui Liu, Jinping Wan, Chandrasekar Durairaj, Gyorgy F. Ambrus, Ke Wu, Danny T. Dinh
  • Patent number: 9981938
    Abstract: Disclosed herein are compounds according to Formulas 1-12, compositions comprising these compounds, and methods of lowering intraocular pressure (IOP) or causing hair growth, and methods of using the same.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: May 29, 2018
    Assignee: ALLERGAN, INC.
    Inventors: Robert M. Burk, David W. Old, Wha Bin Im, Richard S. Graham, Mu-Lan Lee
  • Publication number: 20180071308
    Abstract: Disclosed herein are methods, compounds, and compositions for fat reduction, and in particular fat reduction without significant hair growth and/or additional hair growth.
    Type: Application
    Filed: September 29, 2017
    Publication date: March 15, 2018
    Inventors: Neil J. Poloso, Jenny Wang, David F. Woodward, Robert M. Burk
  • Patent number: 9889142
    Abstract: Prostamide-containing biodegradable intraocular implants, prostamide compounds, prostamide-containing pharmaceutical compositions, and methods for making and using such implants and compositions for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: February 13, 2018
    Assignee: Allergan, Inc.
    Inventors: Patrick M. Hughes, Jie Shen, Michael R. Robinson, David F. Woodward, Robert M. Burk, Hui Liu, Jinping Wan, Chandrasekar Durairaj, Gyorgy F. Ambrus, Ke Wu, Danny T. Dinh
  • Patent number: 9890118
    Abstract: Disclosed herein are compositions comprising an amide related to a prostaglandin and a biogenic amine. Other aspects relate to certain chemical compounds, pharmaceutical compositions, and methods of treating glaucoma.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: February 13, 2018
    Assignee: ALLERGAN, INC.
    Inventors: David F. Woodward, Robert M. Burk
  • Patent number: 9795615
    Abstract: Disclosed herein are methods, compounds, and compositions for fat reduction, and in particular fat reduction without significant hair growth and/or additional hair growth.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: October 24, 2017
    Assignee: ALLERGAN, INC.
    Inventors: Neil J. Poloso, Jenny Wang, David F. Woodward, Robert M. Burk